NEWARK, Calif. – December 10, 2024 – InCarda Therapeutics, a clinical stage biopharmaceutical company developing novel therapeutics for cardiac arrythmias, has announced that Myles Greenberg, MD, MBA will serve as its new president and CEO. Dr. Greenberg joins the company as it advances clinical development...
September 30, 2024 SAN FRANCISCO--(BUSINESS WIRE)--InCarda Therapeutics, Inc. (“InCarda”), a privately-held biopharmaceutical company announces results from the RESTORE-1 Phase 3 trial and plans for continued development. • Analysis of the results of the RESTORE-1 Phase 3 trial following its premature termination demonstrated statistically significant cardioversion of...
Data Demonstrate Orally Inhaled Flecainide May Provide a Safe, Effective, and Convenient First-Line Treatment Option for Cardioversion of Recent-Onset Newly Diagnosed and Paroxysmal Atrial Fibrillation Topline Results from the Ongoing Pivotal Phase 3 RESTORE-1 Trial of InRhythm Expected in Early 2024 SAN FRANCISCO, Nov. 07, 2022 (GLOBE...
Robert Lisicki Appointed as New Chief Executive Officer and Board Member; Possesses Broad Commercial and Public Company Experience Grace E, Colón, Ph.D., Stepping Aside Following Nearly Ten Years as President and CEO; Will Serve as Consultant to Ensure Smooth Leadership Transition SAN FRANCISCO, CA – October 4,...
Phase 2 INSTANT study results demonstrate conversion with inhaled flecainide leads to rapid reduction in ventricular rate and alleviation of atrial fibrillation-related symptoms; the study also demonstrates the potential to reduce healthcare costs related to acute episodes of atrial fibrillation [caption id="attachment_23407" align="aligncenter" width="1782"] Dr. John...
Single Pivotal Phase 3 Trial to Support Filing of New Drug Application Positive Phase 2 Efficacy and Safety Data for InRhythm Recently Highlighted as “Editor’s Pick” in Circulation: Arrhythmia and Electrophysiology SAN FRANCISCO, CA – July 26, 2022 – InCarda Therapeutics, Inc. (“InCarda”), a privately-held biopharmaceutical company...
[caption id="attachment_23373" align="aligncenter" width="800"] Dr. Chris Dufton, SVP of Clinical Development, answering questions about INSTANT P2 at HRS 2022 in San Francisco.[/caption] Phase 2 INSTANT study results demonstrate rapid and reproducible restoration of normal heart rhythm with symptom resolution and a predictable and favorable safety profile...
Our VP of Product Development, Mick Hurrey, will be presenting at RDD on May 3, 2022. More information below: ...
The original article titled “Open-Label, Multicenter Study of Flecainide Acetate Oral Inhalation Solution for Acute Conversion of Recent-Onset, Symptomatic Atrial Fibrillation to Sinus Rhythm” published in the peer-reviewed journal, Circulation: Arrhythmia and Electrophysiology San Francisco, California, March 15, 2022 – InCarda Therapeutics, Inc. (InCarda) announces that...
Harry J.G.M. Crijns, Arif Elvan, Nadea Al-Windy, Ype S. Tuininga, Erik Badings, Ismail Aksoy, Isabelle C. Van Gelder, Prashanti Madhavapeddi, A. John Camm, Peter R. Kowey, Jeremy N. Ruskin, Luiz Belardinelli and the INSTANT Investigators* Originally published 24 Feb 2022 https://doi.org/10.1161/CIRCEP.121.010204Circulation: Arrhythmia and Electrophysiology. 2022;15 Click here...